TIMOPTIC IN OCUDOSE Drug Patent Profile

Which patents cover Timoptic In Ocudose, and what generic alternatives are available?

Timoptic In Ocudose is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in TIMOPTIC IN OCUDOSE is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timoptic In Ocudose

A generic version of TIMOPTIC IN OCUDOSE was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOPTIC IN OCUDOSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	78
Patent Applications:	4,462
Drug Prices:	Drug price information for TIMOPTIC IN OCUDOSE
What excipients (inactive ingredients) are in TIMOPTIC IN OCUDOSE?	TIMOPTIC IN OCUDOSE excipients list
DailyMed Link:	TIMOPTIC IN OCUDOSE at DailyMed

See drug prices for TIMOPTIC IN OCUDOSE

Pharmacology for TIMOPTIC IN OCUDOSE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TIMOPTIC IN OCUDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986	AT3	RX	Yes	Yes
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986	AT3	RX	Yes	Yes

Expired US Patents for TIMOPTIC IN OCUDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986

International Patents for TIMOPTIC IN OCUDOSE

See the table below for patents covering TIMOPTIC IN OCUDOSE around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	7605752
Canada	954863
Yugoslavia	32950
Sweden	389102	MELLANPRODUKT TILL ANVENDNING FOR FRAMSTELLNING AV 1,2,5-TIADIAZOLFORENINGAR MED BETA-ADRENERGISKA BLOCKERINGSEGENSKAPER SAMT FORFARANDE FOR FRAMSTELLNING AV DENNA
United Kingdom	1264558
Yugoslavia	22278

Supplementary Protection Certificates for TIMOPTIC IN OCUDOSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306

TIMOPTIC IN OCUDOSE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Timoptic in Ocudose

Introduction

Timoptic in Ocudose, a preservative-free timolol maleate ophthalmic solution, is a crucial medication in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. This article delves into the market dynamics and financial trajectory of this drug, highlighting key factors influencing its market position and revenue growth.

Market Overview of Ophthalmic Drugs

The global ophthalmic drugs market has been robust and is expected to register a steady revenue growth over the forecast period of 2021 to 2028. This growth is driven by increasing prevalence of eye diseases such as presbyopia, macular degeneration, and diabetic retinopathy, particularly among the elderly population[3].

Indications and Usage

Timoptic in Ocudose is specifically indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It is particularly beneficial for patients sensitive to preservatives, such as benzalkonium chloride, making it a preferred option in such cases[1][4][5].

Market Drivers

Several factors are driving the demand for Timoptic in Ocudose:

Increasing Prevalence of Eye Diseases

The rising prevalence of chronic eye diseases is a significant driver. As the global population ages, the incidence of conditions like glaucoma, presbyopia, and macular degeneration increases, thereby boosting the demand for ophthalmic drugs like Timoptic in Ocudose[3].

Advancements in Healthcare

Rapid advancements in the healthcare and medical sectors, including the adoption of advanced devices and equipment, contribute to the growth of the ophthalmic drugs market. Improving healthcare facilities and systems also play a crucial role[3].

Regulatory Approvals

Recent FDA approvals for generic versions of Timolol Maleate Ophthalmic Solution, such as the one by Amring Pharmaceuticals Inc., have expanded the market availability of this drug. This approval has enabled more patients to access the medication, potentially increasing its market share[4].

Competitive Landscape

The global ophthalmic drugs market is competitive, with various players operating at regional and global levels. Key players are adopting strategies such as R&D investments, license agreements, partnerships, mergers and acquisitions, and collaborations to gain a robust footing in the market. The entry of generic versions, like the one by Amring Pharmaceuticals, adds to the competitive dynamics[3][4].

Financial Performance

Revenue Growth

Timoptic in Ocudose, as part of the broader ophthalmic drugs market, has seen significant revenue growth. For instance, Bausch Health, a major player in the eye health segment, reported strong performance from its leading brands, although specific financial data for Timoptic in Ocudose is not detailed in their reports. However, the overall growth in the eye health segment indicates a positive financial trajectory for such products[2].

Market Size and Forecast

The global ophthalmic drugs market size was robust in 2020 and is expected to continue growing steadily. This growth trend suggests that products like Timoptic in Ocudose will continue to contribute significantly to the overall revenue of the ophthalmic drugs market[3].

Challenges and Risks

Side Effects and Drug Interactions

While Timoptic in Ocudose is effective, it comes with potential side effects such as burning and stinging upon instillation, and more serious cardiovascular effects in some patients. These factors can impact patient compliance and market growth. Additionally, interactions with other beta-adrenergic blocking agents can pose risks, necessitating careful patient monitoring[1].

Economic Factors

The ongoing pandemic has introduced challenges such as shortages of medicines and healthcare devices, which can impact the supply chain and availability of Timoptic in Ocudose. However, these challenges also present opportunities for market players to adapt and innovate[3].

Key Takeaways

• Growing Demand: The increasing prevalence of eye diseases drives the demand for ophthalmic drugs like Timoptic in Ocudose.
• Regulatory Approvals: Recent FDA approvals for generic versions expand market availability.
• Competitive Market: The ophthalmic drugs market is highly competitive, with key players adopting various strategies to gain market share.
• Financial Growth: The overall ophthalmic drugs market is expected to grow steadily, indicating a positive financial trajectory for Timoptic in Ocudose.
• Challenges: Side effects, drug interactions, and economic factors pose risks that need to be managed.

FAQs

What is Timoptic in Ocudose used for?

Timoptic in Ocudose is used for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[1][4][5].

What are the common side effects of Timoptic in Ocudose?

Common side effects include burning and stinging upon instillation, headache, asthenia/fatigue, and chest pain. More serious cardiovascular effects can also occur[1].

Who is at risk from using Timoptic in Ocudose?

Patients with a history of cardiac failure or those receiving other beta-adrenergic blocking agents are at higher risk and should be monitored carefully[1].

How does the competitive landscape affect Timoptic in Ocudose?

The competitive landscape is driven by R&D investments, partnerships, and the entry of generic versions, which can impact market share and pricing strategies[3][4].

What are the key drivers of the ophthalmic drugs market?

Key drivers include the increasing prevalence of eye diseases, advancements in healthcare, and improving healthcare facilities and systems[3].

Sources

1. RxList: Timoptic in Ocudose (Timolol Maleate Ophthalmic Solution) - RxList
2. Bausch Health: 4Q & FY 2021 - Financial Results - Bausch Health Companies Inc.
3. BioSpace: Ophthalmic Drugs Market Demand 2022-2028 - BioSpace
4. Business Wire: Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%
5. DailyMed: TIMOPTIC IN OCUDOSE- timolol maleate solution - DailyMed